%0 Journal Article %1 GAUTRET2020101663 %A Gautret, Philippe %A Lagier, Jean-Christophe %A Parola, Philippe %A Hoang, Van Thuan %A Meddeb, Line %A Sevestre, Jacques %A Mailhe, Morgane %A Doudier, Barbara %A Aubry, Camille %A Amrane, Sophie %A Seng, Piseth %A Hocquart, Marie %A Eldin, Carole %A Finance, Julie %A Vieira, Vera Esteves %A Tissot-Dupont, Hervé Tissot %A Honoré, Stéphane %A Stein, Andreas %A Million, Matthieu %A Colson, Philippe %A Scola, Bernard La %A Veit, Véronique %A Jacquier, Alexis %A Deharo, Jean-Claude %A Drancourt, Michel %A Fournier, Pierre Edouard %A Rolain, Jean-Marc %A Brouqui, Philippe %A Raoult, Didier %D 2020 %J Travel Medicine and Infectious Disease %K (h)cq antiviral azm covid-19 %P 101663 %R https://doi.org/10.1016/j.tmaid.2020.101663 %T Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study %U http://www.sciencedirect.com/science/article/pii/S1477893920301319 %X Background We need an effective treatment to cure COVID-19 patients and to decrease virus carriage duration. Methods We conducted an uncontrolled, non-comparative, observational study in a cohort of 80 relatively mildly infected inpatients treated with a combination of hydroxychloroquine and azithromycin over a period of at least three days, with three main measurements: clinical outcome, contagiousness as assessed by PCR and culture, and length of stay in infectious disease unit (IDU). Results All patients improved clinically except one 86 year-old patient who died, and one 74 year-old patient still in intensive care. A rapid fall of nasopharyngeal viral load was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% of patients at Day5. Consequently patients were able to be rapidly discharged from IDU with a mean length of stay of five days. Conclusion We believe there is urgency to evaluate the effectiveness of this potentially-life saving therapeutic strategy at a larger scale, both to treat and cure patients at an early stage before irreversible severe respiratory complications take hold and to decrease duration of carriage and avoid the spread of the disease. Furthermore, the cost of treatment is negligible.

@article{GAUTRET2020101663, abstract = {Background We need an effective treatment to cure COVID-19 patients and to decrease virus carriage duration. Methods We conducted an uncontrolled, non-comparative, observational study in a cohort of 80 relatively mildly infected inpatients treated with a combination of hydroxychloroquine and azithromycin over a period of at least three days, with three main measurements: clinical outcome, contagiousness as assessed by PCR and culture, and length of stay in infectious disease unit (IDU). Results All patients improved clinically except one 86 year-old patient who died, and one 74 year-old patient still in intensive care. A rapid fall of nasopharyngeal viral load was noted, with 83% negative at Day7, and 93% at Day8. Virus cultures from patient respiratory samples were negative in 97.5% of patients at Day5. Consequently patients were able to be rapidly discharged from IDU with a mean length of stay of five days. Conclusion We believe there is urgency to evaluate the effectiveness of this potentially-life saving therapeutic strategy at a larger scale, both to treat and cure patients at an early stage before irreversible severe respiratory complications take hold and to decrease duration of carriage and avoid the spread of the disease. Furthermore, the cost of treatment is negligible.}, added-at = {2020-04-29T18:28:39.000+0200}, author = {Gautret, Philippe and Lagier, Jean-Christophe and Parola, Philippe and Hoang, Van Thuan and Meddeb, Line and Sevestre, Jacques and Mailhe, Morgane and Doudier, Barbara and Aubry, Camille and Amrane, Sophie and Seng, Piseth and Hocquart, Marie and Eldin, Carole and Finance, Julie and Vieira, Vera Esteves and Tissot-Dupont, Hervé Tissot and Honoré, Stéphane and Stein, Andreas and Million, Matthieu and Colson, Philippe and Scola], Bernard [La and Veit, Véronique and Jacquier, Alexis and Deharo, Jean-Claude and Drancourt, Michel and Fournier, Pierre Edouard and Rolain, Jean-Marc and Brouqui, Philippe and Raoult, Didier}, biburl = {https://www.bibsonomy.org/bibtex/2bf9c9eebfcfeab3a0de2d2f69807e670/fordham1}, description = {Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study - ScienceDirect}, doi = {https://doi.org/10.1016/j.tmaid.2020.101663}, interhash = {89c68a6d69eb06985c60a59493fe6f08}, intrahash = {bf9c9eebfcfeab3a0de2d2f69807e670}, issn = {1477-8939}, journal = {Travel Medicine and Infectious Disease}, keywords = {(h)cq antiviral azm covid-19}, note = {This is the second Marseille study}, pages = 101663, timestamp = {2020-04-29T18:28:39.000+0200}, title = {Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study}, url = {http://www.sciencedirect.com/science/article/pii/S1477893920301319}, year = 2020 }